News & Events
Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
September 12, 2011
Collaboration to investigate potential of AtuPLEX™ in the development of novel microRNA therapeutics targeting cancer London, UK & Nijmegen/Utrecht, Netherlands, September 12, 2011 - Silence Therapeutics pl...
SomantiX announces establishment of Scientific Advisory Board
July 07, 2011
Amsterdam (the Netherlands) - July 7, 2011 - SomantiX B.V., a biotech company focused on the development of new angiogenesis inhibitors, announces the establishment of its Scientific Advisory Board. Tumor...
ORCA Therapeutics announces Grant of European Patent covering its proprietary T1 oncolytic adenovirus technology
July 04, 2011
Amsterdam, The Netherlands - July 4th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has secured key intellectual prop...
Aglaia announces sale of portfolio company Syntarga
June 23, 2011
Bilthoven, June 23, 2011 - Aglaia Oncology Fund is pleased to announce the acquisition of its portfolio company Syntarga B.V. b...Read more
ISA Pharmaceuticals closes a License Agreement with Transgene aimed at the development of novel vaccines for TB
May 26, 2011
Leiden, The Netherlands, May 26th, 2011 - ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Tra...
Merus and ChromaCon receive a € 1.8 million project grant for the discovery and development of bispecific antibodies for therapy of advanced breast cancer
May 16, 2011
Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 - Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bis...
ISA Pharmaceuticals and Prosensa receive Mibiton funding for peptide manufacturing facility
May 12, 2011
Leiden, The Netherlands, April 26th , 2011 - ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that Mibiton supports IS...
InteRNA Technologies Strengthens its R&D Team
April 29, 2011
Nijmegen/Utrecht, The Netherlands, April 29th, 2011 - InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce...
ISA Pharmaceuticals embarks on EUR 4 million Cancer Vaccine development track awarded by CTMM
March 22, 2011
ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, announced that CTMM, an agency of the Dutch Ministry of Economic Affairs, has awarded...
Merus receives € 0.75 million grant for the discovery and development of Oligoclonics™ antibody therapy for colon cancer.
January 05, 2011
Utrecht, The Netherlands, January 5th 2010 ‐ Merus announced today that it has received a € 0.75 million grant for the discovery and development of an antibody combination therapy for colon cancer using its...
Press release Innovation Credit_InteRNA
November 16, 2010
Date: 16 November, 2010 InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company developing path...
KWF Kankerbestrijding reikt KWO-prijzen 2010 uit.
October 12, 2010
6 mln euro voor tumorimmunologie en langetermijngevolgen kankerbehandeling 7 december 2010 - Prof.dr.ir. Floor van Leeuwen (NKI-AVL), prof.dr. Kees Melief (LUMC) en prof.dr Carl Figdor (UMC St. Radboud) ont...
Dr. Wolfgang Berthold joins Supervisory Board Merus
September 20, 2010
Utrecht, the Netherlands (September 20, 2010) - Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board. "We are delighted to appoint Wolf Ber...
InteRNA Technologies announces establishment of Scientific Advisory Board
July 08, 2010
Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of it...
Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP® for phase III clinical trials
June 02, 2010
Bubendorf, Switzerland and Leiden, Netherlands, Bachem (SIX: BANB) and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of...
Merus Announces Publication of the Generation of Single, Clonal Cell lines
June 02, 2010
Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the 'Early View' section of the journal Biotechnology and Bioengineering that demonstrate for the first time...
Syntarga Announces Additional Antibody-Drug Conjugate Collaborations
May 31, 2010
Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements c...
Syntarga Announces Two Antibody-Drug Conjugate Collaborations with Top-tier Biopharmaceutical Companies
March 03, 2010
Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces today that it entered into research collaborations with two undisclosed top-15 pharma companies. These latest agreements, adding t...
Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund
January 29, 2010
Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fu...
Merus receives EuroTransBio Grant
December 15, 2009
Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the developme...